Advertisement
ABVX vs HRTX
Which Stock Would AI Choose? Abivax (ABVX) vs. Heron Therapeutics (HRTX) Stock Comparison
Key Takeaways
- Scale gap: ABVX is a roughly $7.7 billion market-cap, late-stage clinical biotech, while HRTX is a micro-cap commercial-stage biotech with a market cap near $57 million.
- Balance-sheet strength: Abivax holds cash runway into late 2029, whereas Heron's cash position has tightened alongside an adverse patent ruling.
- Catalyst profile: Abivax is progressing toward a U.S. regulatory filing for obefazimod, while Heron has withdrawn its 2026 guidance amid CINVANTI patent litigation.
- Risk posture: Abivax carries clinical and execution risk ahead of launch; Heron carries financing and competitive-generic risk across its commercial franchise.
- Momentum: Both stocks have traded lower in recent months, but for fundamentally different reasons — dilution and deeper losses versus litigation uncertainty.
- For deeper context on either name, explore ABVX Major News and ABVX Today's Price Move, or HRTX Major News and HRTX Today's Price Move.
- To see how AI trading bots are currently positioning across names like these, visit the Trending AI Robots page.
Introduction
Biotechnology stocks often look similar on the surface, yet ABVX (Abivax) and HRTX (Heron Therapeutics) sit at opposite ends of the risk spectrum. Abivax is a French clinical-stage company with a large capitalization and a late-stage inflammatory-bowel-disease pipeline, while Heron is a commercial-stage acute-care and oncology company trading at a small fraction of Abivax's valuation. Comparing them helps investors weigh a deep-pipeline, pre-revenue growth story against a revenue-generating but litigation-pressured franchise. The contrast is most relevant for traders and investors assessing relative performance, market positioning, and how much clinical versus commercial risk they are willing to carry.
ABVX Overview and Recent Performance
Abivax develops therapies for chronic inflammatory diseases, with its lead candidate obefazimod targeting ulcerative colitis (UC) and Crohn's disease. The company recently reported a positive pre-NDA (New Drug Application) interaction with the U.S. FDA and expects to file for U.S. approval of obefazimod in UC around the end of 2026, with Crohn's disease Phase 2b topline data anticipated in mid-2027.
Recent market activity has been pressured. The shares pulled back substantially from earlier 2026 levels, with a year-to-date decline reported near the mid-30% range and a 52-week range spanning roughly $70 to $149. The retreat coincided with widening quarterly losses, which deepened as research-and-development spending and share-based compensation rose ahead of a potential commercial launch. A substantial equity offering raised roughly $920 million, extending projected cash runway into late 2029 but also introducing dilution. Analysts have largely maintained Buy ratings, and the stock retains a comparatively robust cash position for a pre-revenue biotech.
HRTX Overview and Recent Performance
Heron Therapeutics is a commercial-stage biotechnology company focused on acute-care and oncology products, including ZYNRELEF (an extended-release local anesthetic), APONVIE (for postoperative nausea), and the antiemetics CINVANTI and SUSTOL. Its acute-care portfolio has shown strong year-over-year growth, with ZYNRELEF and APONVIE demand climbing in recent quarters.
However, the broader story has been overshadowed by an adverse patent ruling affecting CINVANTI, its largest revenue-generating product. In response, Heron withdrew its full-year 2026 guidance, citing uncertainty over potential generic competition, and announced it was evaluating strategic alternatives while tightening spending. The shares have traded near the low end of a 52-week range spanning roughly $0.26 to $1.58, and the company's market capitalization has compressed to well under $100 million. Cash and short-term investments stood near $43 million at mid-year, and at least one analyst downgraded the stock following the litigation update.
Trending AI Robots
Tickeron maintains hundreds of AI trading bots that collectively scan thousands of tickers, each with its own trading style, strategy, timeframe, performance record, and universe of securities. Not every bot suits every market regime, which is why Tickeron curates only the most promising and best-fit strategies into its Trending AI Robots section. These curated bots are selected for their alignment with current market conditions, and their published statistics span a wide range of risk profiles, holding periods, and win rates — giving traders a menu of quantitative approaches rather than a single one-size-fits-all signal. If you want to see which automated strategies are currently favored across names like these, explore the Trending AI Robots page.
Head-to-Head Comparison
The two companies differ sharply on business model. Abivax is pre-revenue and clinical, deriving essentially all of its value from pipeline milestones and regulatory progress. Heron is generating meaningful revenue — annual sales in the $150 million range — but its economics are challenged by litigation and a need to preserve cash.
On growth drivers, Abivax's thesis rests on a single de-risked asset moving toward commercialization, while Heron's growth depends on expanding adoption of ZYNRELEF and APONVIE even as its oncology franchise faces competitive pressure. Sector exposure also differs: Abivax is concentrated in inflammatory bowel disease, whereas Heron spans acute care and oncology supportive care.
On momentum and sentiment, both names have trended lower, but the drivers diverge. Abivax's decline reflects execution-stage dilution and deeper losses; Heron's reflects litigation uncertainty and financing risk. Abivax offers a strong cash runway and analyst support, while Heron offers near-term commercial revenue but a more constrained balance sheet.
Tickeron AI Verdict
Based on observable factors — trend consistency, balance-sheet stability, catalyst clarity, and relative positioning — Tickeron's AI would likely favor ABVX at present. The name combines a defined regulatory path, a multi-year cash runway, and a comparatively stable large-cap profile, even amid short-term price weakness. Heron's litigation overhang, withdrawn guidance, and compressed market capitalization introduce higher uncertainty that quantitative models tend to discount. That said, this is a probabilistic assessment rather than a definitive outcome: a favorable resolution for Heron or a clinical setback for Abivax could quickly alter relative positioning. Traders should weigh these trade-offs against their own risk tolerance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABVX is a StrongBuy and HRTX is a Buy.
ABVX in +4.98% Uptrend, rising for three consecutive days on November 10, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ABVX advanced for three days, in 154 of 184 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ABVX's RSI Indicator exited the oversold zone, 11 of 18 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 61%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 25 of 32 cases where ABVX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on ABVX as a result. In 39 of 50 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for ABVX just turned positive on October 14, 2026. Looking at past instances where ABVX's MACD turned positive, the stock continued to rise in 30 of 38 cases over the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABVX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for ABVX entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. ABVX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.427) is normal, around the industry mean (3.498). P/E Ratio (-16.084) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (192.308) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABVX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
HRTX in upward trend: price rose above 50-day moving average on November 09, 2026
HRTX moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend. In 33 of 38 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 60 cases where HRTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on HRTX as a result. In 66 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for HRTX just turned positive on November 09, 2026. Looking at past instances where HRTX's MACD turned positive, the stock continued to rise in 30 of 39 cases over the following month. The odds of a continued upward trend are 77%.
Following a +27.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where HRTX advanced for three days, in 181 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The 10-day moving average for HRTX crossed bearishly below the 50-day moving average on October 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HRTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
HRTX broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for HRTX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. HRTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.496) is normal, around the industry mean (3.498). P/E Ratio (-1.542) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.387) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HRTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
HRTX | ||
|---|---|---|
OUTLOOK RATING 1..100 | 46 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 78 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 64 | |
P/E GROWTH RATING 1..100 | 12 | |
SEASONALITY SCORE 1..100 | 26 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| ABVX | HRTX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 61% | N/A |
| Stochastic ODDS (%) | 2 days ago 78% | 2 days ago 87% |
| Momentum ODDS (%) | 2 days ago 78% | 2 days ago 81% |
| MACD ODDS (%) | 2 days ago 79% | 2 days ago 77% |
| TrendWeek ODDS (%) | 2 days ago 82% | 2 days ago 83% |
| TrendMonth ODDS (%) | 2 days ago 84% | 2 days ago 87% |
| Advances ODDS (%) | 2 days ago 84% | 2 days ago 85% |
| Declines ODDS (%) | 10 days ago 81% | 13 days ago 89% |
| BollingerBands ODDS (%) | N/A | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABVX’s FA Score shows that 1 FA rating(s) are green while HRTX’s FA Score has 1 green FA rating(s).
- ABVX’s FA Score: 1 green, 4 red.
- HRTX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABVX’s TA Score shows that 5 TA indicator(s) are bullish while HRTX’s TA Score has 5 bullish TA indicator(s).
- ABVX’s TA Score: 5 bullish, 2 bearish.
- HRTX’s TA Score: 5 bullish, 4 bearish.
Price Growth
ABVX (@Biotechnology) experienced а +1.45% price change this week, while HRTX (@Biotechnology) price change was +31.40% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
ABVX is expected to report earnings on Dec 21, 2026.
HRTX is expected to report earnings on Mar 04, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ABVX and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABVX has been loosely correlated with IMNN. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ABVX jumps, then IMNN could also see price increases.
| Ticker / NAME | Correlation To ABVX | 1D Price Change % | ||
|---|---|---|---|---|
| ABVX | 100% | +3.45% | ||
| IMNN - ABVX | 58% Loosely correlated | -12.79% | ||
| FULC - ABVX | 57% Loosely correlated | N/A | ||
| HRTX - ABVX | 44% Loosely correlated | +0.94% | ||
| CELC - ABVX | 43% Loosely correlated | -4.72% | ||
| XENE - ABVX | 38% Loosely correlated | +2.32% | ||
More | ||||
HRTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, HRTX has been loosely correlated with FULC. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if HRTX jumps, then FULC could also see price increases.
| Ticker / NAME | Correlation To HRTX | 1D Price Change % | ||
|---|---|---|---|---|
| HRTX | 100% | +0.94% | ||
| FULC - HRTX | 47% Loosely correlated | N/A | ||
| AMRN - HRTX | 44% Loosely correlated | +0.09% | ||
| ABVX - HRTX | 44% Loosely correlated | +3.45% | ||
| SION - HRTX | 41% Loosely correlated | +3.64% | ||
| TENX - HRTX | 40% Loosely correlated | -5.06% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| TSYY | 18.70 | 0.02 | +0.13% |
| GraniteShares YieldBOOST TSLA ETF (TSYY) | |||
| SDVY | 42.93 | 0.05 | +0.12% |
| First Trust SMID Cap Rising Dividend Achievers ETF (SDVY) | |||
| GSPY | 41.64 | -0.15 | -0.36% |
| Gotham Enhanced 500 ETF (GSPY) | |||
| ECF | 11.36 | -0.21 | -1.82% |
| Ellsworth Growth and Income Fund Ltd | |||
| SMU | 6.08 | -0.51 | -7.74% |
| Tradr 2X Long SMR Daily ETF (SMU) | |||